{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:29:36Z","timestamp":1765546176487,"version":"3.41.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ijcard.2016.11.217","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T08:17:02Z","timestamp":1478852222000},"page":"113-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy"],"prefix":"10.1016","volume":"229","author":[{"given":"Javeed Ahmad","family":"Tantray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Pratap","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiser","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. Shiva","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2016.11.217_bb0005","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/01.CIR.97.6.596","article-title":"Emerging epidemic of cardiovascular diseases in developing countries","volume":"97","author":"Reddy","year":"1998","journal-title":"Circulation"},{"issue":"9208","key":"10.1016\/j.ijcard.2016.11.217_bb0010","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0140-6736(00)99016-0","article-title":"Gene expression in distinct regions of the heart","volume":"355","author":"Thum","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijcard.2016.11.217_bb0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tips.2006.11.002","article-title":"Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system","volume":"28","author":"Larsen","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ijcard.2016.11.217_bb0025","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.11.217_bb0030","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.11.217_bb0035","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.11.217_bb0040","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","article-title":"The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans","volume":"269","author":"de Morais","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2016.11.217_bb0045","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","article-title":"Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese","volume":"46","author":"de Morais","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.11.217_bb0050","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0022-3565(24)34944-4","article-title":"A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin","volume":"290","author":"Ibeanu","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijcard.2016.11.217_bb0055","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00008571-200212000-00004","article-title":"Identification and functional characterization of new potentially defective alleles of human CYP2C19","volume":"12","author":"Blaisdell","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ijcard.2016.11.217_bb0060","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2133\/dmpk.19.236","article-title":"A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4\u2032-hydroxylation","volume":"19","author":"Morita","year":"2004","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ijcard.2016.11.217_bb0065","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","article-title":"A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants","volume":"79","author":"Sim","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2016.11.217_bb0070","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0022-3565(24)36606-6","article-title":"Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele","volume":"281","author":"Xiao","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijcard.2016.11.217_bb0075","first-page":"45","article-title":"Microtechnique pour l'etude des chromosomes Humains a partir d'une culture de leucocytes Sanguins","volume":"7","author":"De grouchy","year":"1965","journal-title":"Ann Genet. (Paris)"},{"issue":"4","key":"10.1016\/j.ijcard.2016.11.217_bb0080","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.1985.194","article-title":"Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations","volume":"38","author":"Nakamura","year":"1985","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.ijcard.2016.11.217_bb0085","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2125.1985.tb02673.x","article-title":"Genetic polymorphism of mephenytoin p(4\u2032)-hydroxylation: difference between Orientals and Caucasians","volume":"19","author":"Jurima","year":"1985","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ijcard.2016.11.217_bb0090","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/clpt.1992.38","article-title":"Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S mephenytoin","volume":"51","author":"Bertilsson","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ijcard.2016.11.217_bb0095","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/clpt.1989.126","article-title":"Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese","volume":"46","author":"Horai","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ijcard.2016.11.217_bb0100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/clpt.1992.125","article-title":"Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics","volume":"52","author":"Sohn","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.ijcard.2016.11.217_bb0105","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.11.217_bb0110","series-title":"Pharmacogenetics of Drug Metabolism","first-page":"657","article-title":"Genetic polymorphism of S mephenytoin hydroxylation","author":"Wilkinson","year":"1992"},{"issue":"3","key":"10.1016\/j.ijcard.2016.11.217_bb0115","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1067\/mcp.2000.109365","article-title":"CYP2C19 genetic mutations in North Indians","volume":"68","author":"Lamba","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ijcard.2016.11.217_bb0120","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.atherosclerosis.2011.04.008","article-title":"Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease","volume":"220","author":"Chen","year":"2012","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ijcard.2016.11.217_bb0125","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4103\/0971-6866.142896","article-title":"Prevalence of genetic variants associated with cardiovascular disease risk and drug response in the Southern Indian population of Kerala","volume":"20","author":"Mahadevan","year":"2014","journal-title":"Indian J. Hum. Genet."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316320757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316320757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T11:00:53Z","timestamp":1749726053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316320757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":24,"alternative-id":["S0167527316320757"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.217","relation":{},"ISSN":["0167-5273"],"issn-type":[{"type":"print","value":"0167-5273"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}